Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.
about
Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimensPharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitalsOutcomes in Documented Pseudomonas aeruginosa Bacteremia Treated with Intermittent IV Infusion of Ceftazidime, Meropenem, or Piperacillin-Tazobactam: A Retrospective Study.Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis.Therapeutic drug monitoring in the past 40 years of the Journal of Antimicrobial Chemotherapy.Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline.Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection.Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.Initial Vancomycin Dosing Protocol to Achieve Therapeutic Serum Concentrations in Patients Undergoing Hemodialysis
P2860
Q34570886-F40F0A52-BF60-480D-9F60-1ACFA79D8D55Q35569189-B8BB8796-AB7E-4C4A-AD07-ACB12493259EQ36161206-D9676EBD-00FB-46D4-9AC0-474CB943E2E3Q36287127-BCD864EB-E836-44D9-ADFD-33BC499489CEQ37335840-CB1D53A3-2D38-4B80-A2FA-23B5ABE11C44Q37643628-1B9D4F76-FD31-4800-B1FE-97AD13169BBEQ38073197-6819BC91-D131-488C-8079-E015ADC6D284Q38099393-0A415593-D960-4CE2-89DB-4B186F63332AQ38167345-E2E97A24-1DCA-4BEF-8717-994A205D78F9Q38313276-1EA9CC46-A893-428B-9AEB-5BD3709E3756Q38681779-094F6259-92D8-4838-A3BF-12B13AAA8280Q39011332-61B9577B-23BA-44DB-9FB2-2F520B2EDA84Q39965478-326B10EA-8438-4545-9FBB-8E579686D369Q40073466-E58D3E77-5530-4B6A-86C4-228A9EE381A2Q40092306-A85292CA-60F3-4306-B2DC-A261471A991DQ41827471-07C5858F-F1A6-40B4-8781-1EF2ACEF26FDQ49171086-1CAD6648-6347-49E0-81E6-B92D452CF2BFQ50089280-9B257A50-680B-4B44-9C73-B28562EF2312Q57238274-6F9D9850-90DD-4B12-AC21-034EFF498DDD
P2860
Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacodynamics of empirical ...... on Canadian surveillance data.
@ast
Pharmacodynamics of empirical ...... on Canadian surveillance data.
@en
type
label
Pharmacodynamics of empirical ...... on Canadian surveillance data.
@ast
Pharmacodynamics of empirical ...... on Canadian surveillance data.
@en
prefLabel
Pharmacodynamics of empirical ...... on Canadian surveillance data.
@ast
Pharmacodynamics of empirical ...... on Canadian surveillance data.
@en
P50
P356
P1476
Pharmacodynamics of empirical ...... on Canadian surveillance data.
@en
P304
P356
10.1093/JAC/DKQ348
P407
P577
2010-10-05T00:00:00Z